New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2014
08:57 EDTBAYRY, OMEDOncoMed commences third Phase 1b clinical trial for OMP-54F28
OncoMed Pharmaceuticals (OMED) announced the initiation of patient treatment for its third multi-center Phase 1b clinical trial of OMP-54F28 with carboplatin and paclitaxel in patients with platinum-sensitive ovarian cancer. OMP-54F28 is a first-in-class decoy receptor targeting the Wnt pathway and is part of OncoMed's collaboration with Bayer Pharma AG (BAYRY). The Phase 1b clinical trial of OMP-54F28 in combination with carboplatin and paclitaxel is a dose-escalation study in patients with recurrent platinum-sensitive ovarian cancer. Primary objectives of the trial are to evaluate safety of this combination regimen and determine a recommended Phase 2 dose for OMP-54F28 in combination with carboplatin and paclitaxel. Key secondary and exploratory objectives include evaluation of the pharmacokinetics and pharmacodynamics of OMP-54F28, as well as the efficacy of this combination. Tumor tissue from patients will be used to explore predictive biomarker hypotheses related to the efficacy of OMP-54F28.
News For OMED;BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
08:17 EDTOMEDOncoMed presents data from tarextumab, demcizumab trials
OncoMed Pharmaceuticals presented data in two posters highlighting the company's translational research and biomarker efforts for its tarextumab and demcizumab clinical programs Jakob Dupont, M.D., OncoMed's Chief Medical Officer, stated, "The data from the Phase 1b clinical trials of tarextumab and demcizumab demonstrate that our preclinical understanding of on-target drug activity and predictive biomarkers is being validated in the clinic as we study actual patient tumor samples. In the ALPINE Phase 1b study in advanced pancreatic cancer, we see clear evidence that tarextumab modulates the Notch cancer stem cell pathway in patient samples and that there is a potential association between tumors that show higher levels of Notch3 gene expression and best responses to tarextumab treatment. In the demcizumab poster presentation, a case study is described from our Phase 1b trial in pancreatic cancer in which the tumor response to treatment that occurred in the clinic correlates with what we observe using patient-derived xenograft models. This may provide insights into the development of potential biomarkers of response to demcizumab treatment in that program."
November 20, 2014
08:36 EDTBAYRYZoetis guidance positive, says BMO Capital
Subscribe for More Information
November 19, 2014
07:54 EDTOMEDOncoMed presents biomarker-focused clinical data from Anti-Notch1 Phase 1a trial
Subscribe for More Information
November 18, 2014
05:43 EDTBAYRYRegeneron announces EYLEA injection approved for DME treatment in Japan
Subscribe for More Information
November 14, 2014
07:14 EDTBAYRYAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
09:33 EDTBAYRYZoetis could get bought by Bayer for $53/share, says Jefferies
Subscribe for More Information
November 12, 2014
08:18 EDTBAYRYUBS to hold a conference
Subscribe for More Information
07:53 EDTOMEDLeerink to hold a tour
Subscribe for More Information
06:22 EDTBAYRYZoetis price target raised to $49 from $44 at Citigroup
Citigroup raised its price target for Zoetis (ZTS) shares to $49 after activist Pershing Square confirmed the accumulation of a 10% stake in the company. Citi thinks Pershing is interested in advocating for a sale of Zoetis, potentially to Valeant (VRX) if its bid for Allergan (AGN) fails. Citi believes others, including Bayer (BAYRY), could be interested in acquiring Zoetis. It keeps a Buy rating on the stock.
November 10, 2014
16:07 EDTBAYRYUBS to hold a conference
UBS European Conference is being held in London, England on November 11-12.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use